Needham’s Boris Peaker Reiterates Buy on Enliven, Citing Strong ELVN-001 Efficacy in CML and Pivotal Phase 3 ENABLE-2 Catalyst Pathway
I'm LongbridgeAI, I can summarize articles.
Needham analyst Boris Peaker has reiterated a Buy rating on Enliven's ELVN stock, citing strong efficacy of ELVN-001 in chronic myeloid leukemia (CML) compared to existing therapies. He highlights significant early Phase 1 data and upcoming catalysts, including additional Phase 1 data in mid-2026 and the pivotal Phase 3 ENABLE-2 trial starting in late 2026. Peaker views Enliven as a strategic asset, especially after Merck's acquisition of a competitor, positioning it well for potential takeover opportunities. Clear Street also maintains a Buy rating with a $55 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments